This inventor holds 8 USPTO granted patents and 4 EPO patents. Top assignees: Vertex Pharmaceuticals, Inc., Novartis Ag, Other. Active years: 2005-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Marlborough, MA (US) (2005 - 2010)
- Sudbury, MA (US) (2007 - 2016)
Company Filing History:
5 out of 1,167 
2 out of 3,977 
1 out of 834,513 Years Active: 2005-2016
Title: Ronald Charles Tomlinson: A Pioneer in Tankyrase Inhibitor Research
Introduction
Ronald Charles Tomlinson, an inventive mind located in Sudbury, MA, is known for his significant contributions to pharmaceutical science through his innovative patenting efforts. With a remarkable portfolio comprising eight patents, Tomlinson has focused primarily on developing compounds that address critical health issues, particularly those related to cancer through tankyrase inhibition.
Latest Patents
Among his latest innovations is a patent for 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrmidinyl compounds, designed for use as tankyrase inhibitors. This invention encompasses a range of compounds that have demonstrated potential in the treatment of Wnt signaling and disorders related to tankyrase 1 and 2 signaling, with applications in cancer therapies. Another notable patent by Tomlinson includes 2-piperidin-1-yl-acetamide compounds, which also function as tankyrase inhibitors, further solidifying his role in advancing pharmacological research aimed at combating cancer.
Career Highlights
Tomlinson’s career boasts impressive affiliations with prominent companies in the pharmaceutical sector. He has made substantial contributions while working at Vertex Pharmaceuticals, Inc., and Novartis AG, two leaders in innovative drug development. Through his work, he has not only contributed to product development but has also ensured significant innovations in cancer treatment options.
Collaborations
Throughout his career, Tomlinson has collaborated with talented individuals in the field, such as David J. Lauffer and Alex Aronov. These partnerships have likely played a crucial role in the successful development of his patents and have contributed to his impactful presence in the industry.
Conclusion
Ronald Charles Tomlinson remains a critical figure in the realm of innovative medical research, particularly through his patented work in the development of tankyrase inhibitors. His collaborations, career experiences, and groundbreaking inventions mark him as an influential inventor committed to improving cancer treatment and enhancing pharmaceutical methodologies. As research continues to evolve, Tomlinson’s contributions will undoubtedly pave the way for future advancements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile